Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach
Open Access
- 2 August 2023
- journal article
- research article
- Published by Elsevier in Journal of Biomedical Informatics
- Vol. 145, 104465
Abstract
No abstract availableKeywords
Funding Information
- Alternatives Research and Development Foundation
- Center for Alternatives to Animal Testing
- European Commission
- Research Foundation Flanders
This publication has 37 references indexed in Scilit:
- Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human HepatocytesPLOS ONE, 2014
- Drug-induced Acute Liver FailureClinics in Liver Disease, 2013
- The adverse outcome pathway concept: A pragmatic tool in toxicologyToxicology, 2013
- A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound DevelopmentToxicological Sciences, 2013
- Development of an Adverse Outcome Pathway From Drug-Mediated Bile Salt Export Pump Inhibition to Cholestatic Liver InjuryToxicological Sciences, 2013
- BSEP inhibition – In vitro screens to assess cholestatic potential of drugsToxicology in Vitro, 2012
- Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytesBiochemical and Biophysical Research Communications, 2011
- Bile-acid-induced cell injury and protectionWorld Journal of Gastroenterology, 2009
- Differential Inhibition of Rat and Human Na+-Dependent Taurocholate Cotransporting Polypeptide (NTCP/SLC10A1)by Bosentan: A Mechanism for Species Differences in HepatotoxicityThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis: Pathogenetic and Therapeutic ConsiderationsMolecular Pharmaceutics, 2006